(Q36023598)

11 August 2017

1 reference

title

Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence (English)

1 reference

11 August 2017

1 reference

6

Per Damkier

1 reference

11 August 2017

author name string

Tina Svenstrup Poulsen

1

1 reference

11 August 2017

Pernille Vinholt

2

1 reference

11 August 2017

Hans Mickley

3

1 reference

11 August 2017

Lars Korsholm

4

1 reference

11 August 2017

Søren Risom Kristensen

5

1 reference

11 August 2017

publication date

1 February 2005

1 reference

Basic and Clinical Pharmacology and Toxicology

11 August 2017

published in

1 reference

11 August 2017

volume

96

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

103-110

1 reference

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

P2y(12), a new platelet ADP receptor, target of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2005.PTO960203.X

10.1111/J.1742-7843.2005.PTO960203.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference